Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. (Q36433785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Timothy M Kuzel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Paul R Yarnold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Nicholas Slimack

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

E Allison Lyons

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Dennis W Raisch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Charles L Bennett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

2051-2057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568459%20AND%20SRC:MED&resulttype=core&format=json

Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combina

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

The Research on Adverse Drug Events and Reports (RADAR) project.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

[The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Cisplatin and carboplatin-mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1 alpha and tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Thrombotic thrombocytopenic purpura associated with clopidogrel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Pure red-cell aplasia and epoetin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine-induced systemic capillary leak syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine pulmonary toxicity: CT features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Severe pulmonary toxicity in a patient treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine-induced pulmonary toxicity: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

A report on serious pulmonary toxicity associated with gemcitabine-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Bronchiolitis obliterans organizing pneumonia induced by chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

An Autopsy Case of Acute Pulmonary Toxicity Associated with Gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21808

1 reference

7 January 2021

Severe acute lung injury induced by gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21808

7 January 2021